Oncology Intelligence
Focused analysis of global oncology pipelines, immunotherapy breakthroughs, regulatory acceleration pathways and competitive strategy across major pharmaceutical markets.
Oncology remains the largest therapeutic category globally.
Immuno-oncology, ADCs, targeted therapies and combination regimens are redefining competitive positioning.
Advances in the Treatment of HER2-Mutant Advanced Non-Small Cell Lung Cancer
April 17, 2026
Latest advances in HER2-mutant NSCLC treatment, including ADCs and TKIs such as trastuzumab deruxtecan, zongertinib, and sevabertinib.
From Single-Target Inhibition to Network-Level Intervention: A Paradigm Shift in KRAS-Mutant Cancer Therapy
April 16, 2026
Explore how KRAS-mutant cancer therapy is evolving from single-target inhibition to network-level intervention, reshaping precision oncology.
China Innovative Drug Weekly: RNA, ADC, CAR-T and GLP-1 Drive Global Expansion
April 15, 2026
Weekly update on China’s innovative drug landscape covering RNA therapies, ADC, CAR-T, GLP-1 and global expansion trends.
Latest Advances in Gene Therapy: From Genetic Disorders to Cancer Treatment
April 15, 2026
An overview of gene therapy principles, mechanisms, clinical applications, and future trends from genetic diseases to cancer treatment.
2026 Global Oncology Innovation: The Convergence of ADCs and Bispecific Antibodies
April 11, 2026
Global Liver Cancer Drug Market Size and Outlook 2026: Innovation Driving a New Growth Cycle
April 11, 2026
Gene Editing and Next-Generation Nucleic Acid Therapies: Toward Curative Medicine
April 10, 2026
2026 Global Innovative Drug R&D and Regulatory Dynamics: ADC and Gene Therapies Lead a New Era
April 10, 2026
In 2026, global innovative drug R&D continues to accelerate, with Antibody-Drug Conjugates (ADCs) and gene therapies taking center stage. This article deeply analyzes the latest approval dynamics from the FDA and NMPA, and explores how these cutting-edge technologies are reshaping the landscape of oncology and rare disease treatments.
Global Pharmaceutical Innovation and Regulatory Dynamics in 2026: Breakthroughs in Oncology and Rare Diseases
April 09, 2026
How Bispecific ADCs Overcome Antigen Escape: Technical Mechanisms and Insights
April 07, 2026
A deep dive into how bispecific ADCs overcome antigen escape through dual targeting, enhanced internalization, and optimized payload delivery.
Emerging Trends and Innovations in Oncology Therapeutics: A 2026 Overview
April 06, 2026
Latest Advances in Anti-Angiogenic Therapy (2025–2026)
April 03, 2026
Anti-angiogenic therapy continues to achieve breakthroughs in mechanistic innovation, combination treatment models, and the development of novel drugs, evolving toward greater precision and efficacy.
China’s ADC Global Expansion: 44 Deals, $53.2B in Value, and a Shift to Technology Leadership
April 02, 2026
An in-depth analysis of China’s ADC global expansion, covering 44 deals worth $53.2B and the shift from asset licensing to platform-level innovation.
CAR-T 2.0 Era: Rapid Manufacturing, Dual Targeting and Reduced Toxicity in 2026
April 01, 2026
Explore the CAR-T 2.0 era in 2026, featuring rapid manufacturing, dual-target strategies, reduced toxicity, and expanding applications in oncology and beyond.
How Do PD-1/PD-L1 Inhibitors Work? Mechanisms of Cancer Immunotherapy Explained
March 31, 2026
A deep dive into how PD-1/PD-L1 inhibitors restore T-cell function, block immune escape, and reshape the tumor microenvironment in modern cancer immunotherapy.
Why β₁-Selective Beta-Blockers Remain Important in Cardiovascular Therapy
March 30, 2026
Explore why β₁-selective beta-blockers like bisoprolol remain essential in cardiovascular therapy, with improved safety and targeted mechanisms.
China’s Next-Generation Antiplatelet Drug CG-0255 Enters Clinical Development
March 25, 2026
CG-0255, a next-generation P2Y12 inhibitor from China, shows early clinical progress with potential advantages in safety and rapid onset.
2026 List of Approved Oncology Drugs in China (NMPA Guide) and Practical Reference for Overseas Procurement
March 25, 2026
FGFR Inhibitors: Emerging Targeted Therapies for Rare Skeletal Disorders
March 23, 2026
China Pan-KRAS Breakthrough: BeiGene’s BGB-53038 Enters Clinical Trials
March 23, 2026
BeiGene’s pan-KRAS inhibitor BGB-53038 enters clinical trials, marking new progress in targeting multiple KRAS mutations across solid tumors.